Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease

16 september 2026 uppdaterad av: AbbVie

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of ABBV-1758 in Participants With Alzheimer's Disease

Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Clinical symptoms of the disease may begin with occasional forgetfulness such as misplacement of items, forgetting important dates or events, and may progress to noticeable memory loss, increased confusion and agitation, and eventually, loss of independence and non-responsiveness. The purpose of this study is to test how safe ABBV-1758 is, how well it works, how the body processes it and what effects it has on the body.

ABBV-1758 is an investigational drug being developed for the treatment of Alzheimer's disease. This study is conducted in 3 stages. Stage A is a multiple ascending dose study with a 1 in 5 chance (4:1 randomization) that participants are assigned to receive placebo. Stage B is a dose expansion phase, also using 4:1 randomization for ABBV-1758 or placebo. Stage C enrolls Japanese and Chinese participants with the same randomization scheme. Approximately 210 participants will be enrolled at about 55 sites in the United States, China, and Japan.

Participants will receive intravenous (IV) or subcutaneous (SC) doses of ABBV-1758 or placebo once every 4 weeks (Q4W) for 24 weeks and will be followed for additional 12 weeks in the Follow-up Period. Participants will have the option of participating in a 12-month, blinded Extension Period receiving ABBV-1758 or placebo based on amyloid PET results.

There may be higher treatment burden for participants in this trial compared to their standard of care due to study procedures. Participants will attend regular visits during the study at a hospital or clinic. The safety of the treatment will be checked by medical assessments, blood tests, and completing questionnaires.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

210

Fas

  • Fas 2
  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • California
      • Irvine, California, Förenta staterna, 92614
        • Rekrytering
        • Irvine Center for Clinical Research /ID# 277752
    • Colorado
      • Boulder, Colorado, Förenta staterna, 80301
        • Rekrytering
        • Alpine Clinical Research Center - Boulder - 47th Street /ID# 277856
    • Florida
      • Bradenton, Florida, Förenta staterna, 34207
        • Rekrytering
        • Key Clinical Research LLC /ID# 277800
        • Kontakt:
          • Site Coordinator
          • Telefonnummer: 941-241-5539
      • Clermont, Florida, Förenta staterna, 34711
        • Rekrytering
        • K2 Medical Research - Clermont /ID# 277859
      • Lady Lake, Florida, Förenta staterna, 32159
        • Rekrytering
        • K2 Medical Research - The Villages /ID# 278290
      • Stuart, Florida, Förenta staterna, 34997
        • Rekrytering
        • Alzheimer'S Research And Treatment Center - Stuart /ID# 278206
      • Wellington, Florida, Förenta staterna, 33414
        • Rekrytering
        • Alzheimer's Research And Treatment Center - Wellington /ID# 277749
        • Kontakt:
          • Site Coordinator
          • Telefonnummer: (561) 209-2400
      • Winter Park, Florida, Förenta staterna, 32789
        • Rekrytering
        • Conquest Research - Winter Park /ID# 277760
        • Kontakt:
          • Site Coordinator
          • Telefonnummer: 407-916-0060
    • Massachusetts
      • Watertown, Massachusetts, Förenta staterna, 02472
        • Rekrytering
        • Adams Clinical /ID# 277754
    • Tennessee
      • Cordova, Tennessee, Förenta staterna, 38018
        • Rekrytering
        • Neurology Clinic - Cordova /ID# 277790
    • Texas
      • Dallas, Texas, Förenta staterna, 75231
        • Rekrytering
        • Kerwin Medical Center /ID# 277788
        • Kontakt:
          • Site Coordinator
          • Telefonnummer: 972-433-9100
    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina, 100053
        • Rekrytering
        • Xuanwu Hospital Capital Medical University /ID# 283310
    • Guangdong
      • Guangzhou, Guangdong, Kina, 510260
        • Rekrytering
        • The Second Affiliated Hospital of Guangzhou Medical University /ID# 284295

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

50 år till 90 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Participants meeting all the following criteria for Alzheimer's disease (AD):

    • In regions where timely testing is feasible (e.g., results available within 4 weeks of Visit 1), plasma biomarker that is predictive of elevated brain amyloid at Screening for participants that do not have known elevated brain amyloid based on previous amyloid positron emission tomography (PET) results.
    • Participants with amyloid positron emission tomography PET scan results consistent with significant amyloid pathology (as determined by a Centiloid value of 50 or higher).
  • Participants must have a Mini-Mental State Examination (MMSE) score of 20 or higher at Screening.

Exclusion Criteria:

  • Participants with screening magnetic resonance imaging (MRI) that show evidence of another potential etiology for progressive dementia.

  • Participants who have any current serious conditions or illnesses that are not adequately controlled, or any conditions that, in the investigator's opinion, could interfere with the analyses in this study, including but not limited to psychiatric, neurologic (other than AD), cardiovascular, hepatic, renal, gastroenterological, respiratory, endocrinologic, immunologic, or hematologic, metabolic, pulmonary, ophthalmologic, dermatologic, and/or any history of abnormal laboratory results that are indicative of significant disease(s).

  • Participants who had prior exposure to ABBV-1758 or any history of exposure to anti-amyloid beta monoclonal antibody (mAb) treatment.

  • Participants with other significant pathological findings on brain MRI at screening, including but not limited to:

    • Evidence of vasogenic edema
    • 4 or more microhemorrhages (defined as 10 mm or less at the greatest diameter)
    • Any macrohemorrhage (defined as greater than 10 mm at the greatest diameter)
    • Any superficial siderosis
    • Severe white matter disease

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Sekventiell tilldelning
  • Maskning: Trippel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Stage A-ABBV-1758 Dose A

Participants will receive ABBV-1758 dose A once every 4 weeks (Q4W).

Intravenous (IV) or Subcutaneous (SC)

Subcutaneous (SC)

Placebo-jämförare: Placebo for ABBV-1758 Dose A

Participants will receive Placebo for ABBV-1758.

Intravenous (IV) or Subcutaneous (SC)

Subcutaneous (SC)

Experimentell: Stage A-ABBV-1758 Dose B

Participants will receive ABBV-1758 dose B Q4W.

Intravenous (IV) or Subcutaneous (SC)

Subcutaneous (SC)

Placebo-jämförare: Placebo for ABBV-1758 Dose B

Participants will receive Placebo for ABBV-1758.

Intravenous (IV) or Subcutaneous (SC)

Subcutaneous (SC)

Experimentell: Stage A-ABBV-1758 Dose C

Participants will receive ABBV-1758 dose C Q4W.

Intravenous (IV) or Subcutaneous (SC)

Subcutaneous (SC)

Placebo-jämförare: Placebo for ABBV-1758 Dose C

Participants will receive Placebo for ABBV-1758.

Intravenous (IV) or Subcutaneous (SC)

Subcutaneous (SC)

Experimentell: Stage A-ABBV-1758 Dose D

Participants will receive ABBV-1758 dose D Q4W.

Intravenous (IV) or Subcutaneous (SC)

Subcutaneous (SC)

Placebo-jämförare: Placebo for ABBV-1758 Dose D

Participants will receive Placebo for ABBV-1758.

Intravenous (IV) or Subcutaneous (SC)

Subcutaneous (SC)

Experimentell: Stage B- ABBV-1758 - Expanded Cohort 1

Participants will receive ABBV-1758 dose determined in Stage A Q4W.

Intravenous (IV) or Subcutaneous (SC)

Subcutaneous (SC)

Placebo-jämförare: Placebo for ABBV-1758 - Expanded Cohort 1

Participants will receive Placebo for ABBV-1758.

Intravenous (IV) or Subcutaneous (SC)

Subcutaneous (SC)

Experimentell: Stage B- ABBV-1758- Expanded Cohort 2

Participants will receive ABBV-1758 dose determined in Stage A Q4W.

Intravenous (IV) or Subcutaneous (SC)

Subcutaneous (SC)

Placebo-jämförare: Placebo for ABBV-1758- Expanded Cohort 2

Participants will receive Placebo for ABBV-1758.

Intravenous (IV) or Subcutaneous (SC)

Subcutaneous (SC)

Experimentell: Stage C- ABBV-1758 - Japanese Cohort 1

Participants will receive ABBV-1758 dose determined in Stage A Q4W.

Intravenous (IV) or Subcutaneous (SC)

Subcutaneous (SC)

Placebo-jämförare: Placebo for ABBV-1758 - Japanese Cohort 1

Participants will receive Placebo for ABBV-1758.

Intravenous (IV) or Subcutaneous (SC)

Subcutaneous (SC)

Experimentell: Stage C- ABBV-1758- Japanese Cohort 2

Participants will receive ABBV-1758 dose determined in Stage A Q4W.

Intravenous (IV) or Subcutaneous (SC)

Subcutaneous (SC)

Placebo-jämförare: Placebo for ABBV-1758- Japanese Cohort 2

Participants will receive Placebo for ABBV-1758.

Intravenous (IV) or Subcutaneous (SC)

Subcutaneous (SC)

Experimentell: Stage C- ABBV-1758-Chinese Cohort

Participants will receive ABBV-1758 dose determined in Stage A Q4W.

Intravenous (IV) or Subcutaneous (SC)

Subcutaneous (SC)

Placebo-jämförare: Placebo for ABBV-1758- Chinese Cohort

Participants will receive Placebo for ABBV-1758.

Intravenous (IV) or Subcutaneous (SC)

Subcutaneous (SC)

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Percentage of Participants Experiencing Adverse Events (AEs)
Tidsram: Up to approximately 40 weeks

An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with the treatment. The investigator assesses the relationship of each event to the use of study drug.

Up to approximately 40 weeks
Percentage of Participants with Abnormal Change from Baseline in Clinical Laboratory Test Results
Tidsram: Up to approximately 40 weeks

Number of participants with abnormal change in clinical laboratory test results like hematology will be assessed.

Up to approximately 40 weeks
Percentage of Participants With Amyloid-Related Imaging Abnormalities (ARIA)
Tidsram: Up to approximately 40 weeks

Amyloid related imaging abnormalities represent a spectrum of magnetic resonance imaging findings primarily observed in participants undergoing treatment with anti-amyloid therapies.

Up to approximately 40 weeks
Percentage of Participants with Abnormal Change From Baseline in Vital Sign Measurements
Tidsram: Up to approximately 40 weeks

Number of participants with abnormal change from baseline in vital sign measurements like systolic and diastolic blood pressure will be assessed.

Up to approximately 40 weeks
Percentage of Participants with Abnormal Change From Baseline in Electrocardiograms (ECGs) Parameters
Tidsram: Up to approximately 40 weeks

12-lead resting ECGs will be recorded. Parameters include heart rate, PR interval, QT interval, QRS duration, and QT interval corrected using Fridericia's formula (QTcF).

Up to approximately 40 weeks
Percentage of Participants Experiencing Any Suicidal Ideation or Suicidal Behavior As Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)
Tidsram: Up to approximately 40 weeks

The C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior, with a higher score denoting more severe suicidal ideation and behavior.

Up to approximately 40 weeks
Stage A, B, and C: Change from Baseline in Brain Amyloid Load
Tidsram: Up to approximately 28 Weeks

Measured by amyloid positron emission tomography (PET)

Up to approximately 28 Weeks
Stage A and C: Maximum Plasma Concentration (Cmax) of ABBV-1758
Tidsram: Up to approximately 40 weeks

Cmax of ABBV-1758

Up to approximately 40 weeks
Stage A and C: Time to Cmax (Tmax) of ABBV-1758
Tidsram: Up to approximately 40 weeks

Tmax of ABBV-1758

Up to approximately 40 weeks
Stage A and C: Trough Concentration measured at the end of a dosing interval at steady state (Ctrough) of ABBV-1758
Tidsram: Up to approximately 40 weeks

Ctrough of ABBV-1758

Up to approximately 40 weeks
Stage A and C: Area under the Plasma Concentration-time Curve from Time Zero to the End of the Dosing Interval (AUCtau) of ABBV-1758
Tidsram: Up to approximately 40 weeks

AUCtau of ABBV-1758

Up to approximately 40 weeks
Stage A and C: Average Serum Concentration at Steady-State (Cav,ss) of ABBV-1758
Tidsram: Up to approximately 40 weeks

Cav,ss of ABBV-1758

Up to approximately 40 weeks
Stage A and C: Accumulation ratio for (AUCtau) of ABBV-1758
Tidsram: Up to approximately 40 weeks

AUCtau of ABBV-1758

Up to approximately 40 weeks
Stage A and C: Total Body Clearance (CL) of ABBV-1758
Tidsram: Up to approximately 40 weeks

CL of ABBV-1758

Up to approximately 40 weeks
Stage A and C: Apparent Clearance (CL/F) of ABBV-1758
Tidsram: Up to approximately 40 weeks

CL/F of ABBV-1758

Up to approximately 40 weeks
Stage A and C: Volume of Distribution at Steady-State (Vss)
Tidsram: Up to approximately 40 weeks

Vss of ABBV-1758

Up to approximately 40 weeks
Stage A and C: Apparent Volume of Distribution during the Terminal Phase (Vz)
Tidsram: Up to approximately 40 weeks

Vz of ABBV-1758

Up to approximately 40 weeks
Stage A and C: Terminal Phase Elimination Rate Constant (β) of ABBV-1758
Tidsram: Up to approximately 40 weeks

β of ABBV-1758

Up to approximately 40 weeks
Stage A and C: Terminal Phase Elimination Half-Life (t1/2) of ABBV-1758
Tidsram: Up to approximately 40 weeks

Terminal phase elimination half-life of ABBV-1758

Up to approximately 40 weeks
Stage A and C: Effective Half-Life (T1/2,eff)
Tidsram: Up to approximately 40 weeks

T1/2,eff of ABBV-1758

Up to approximately 40 weeks

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Utredare

  • Studierektor: ABBVIE INC., AbbVie

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

15 maj 2026

Primärt slutförande (Beräknad)

1 oktober 2030

Avslutad studie (Beräknad)

1 oktober 2030

Studieregistreringsdatum

Först inskickad

15 maj 2026

Först inskickad som uppfyllde QC-kriterierna

15 maj 2026

Första postat (Faktisk)

20 maj 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

18 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

16 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Tidsram för IPD-delning

For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

Kriterier för IPD Sharing Access

To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

IPD-delning som stöder informationstyp

  • STUDY_PROTOCOL
  • SAV

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

produkt tillverkad i och exporterad från U.S.A.

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera